Related Experiment Video

Updated: Jan 8, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K

Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma

Li Zhao1

  • 1Department of Gastroenterology, The First People's Hospital of Yuhang Hangzhou 310016, Zhejiang, P. R. China.

International Journal of Clinical and Experimental Medicine
|February 18, 2016
PubMed

Insights

Hirudin, a potential glioma treatment, inhibits ERK/MAPK signaling pathways. This study shows hirudin increases ERK1/2 inactivation, reducing glioma cell growth and promoting apoptosis.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioma is a common and aggressive brain tumor with poor prognosis.
  • The Extracellular signal-Regulated Kinase/Mitogen-Activated Protein Kinase (ERK/MAPK) signaling pathway is implicated in glioma development.
  • Existing treatments for glioma have limited efficacy, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the potential of hirudin as an antineoplastic agent against glioma.
  • To determine if hirudin inhibits the ERK/MAPK signaling pathway in glioma cells.
  • To evaluate the effects of hirudin on glioma cell proliferation, apoptosis, and cell cycle progression.

Main Methods:

  • In vitro study using glioma cell lines.
  • Cell proliferation assessed by MTS assay.
  • Apoptosis detected using Annexin V staining.
  • Cell cycle distribution analyzed by flow cytometry.
  • ERK/MAPK signaling pathway molecules examined via Western blot and immunofluorescence.

Main Results:

  • Hirudin treatment led to increased inactivation of ERK1/2.
  • Down-regulation of the canonical ERK/MAPK signaling pathway was observed.
  • Hirudin significantly affected glioma cell proliferation and apoptosis rates.
  • Changes in cell cycle distribution were noted following hirudin treatment.

Conclusions:

  • Hirudin demonstrates antineoplastic effects on glioma cells in vitro.
  • Hirudin inhibits glioma growth by modulating the ERK/MAPK signaling pathway.
  • Hirudin represents a promising therapeutic candidate for glioma treatment.
Keywords:
ERK/MAPK signalingHirudincell growthglioma

More Related Videos

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment07:55

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment

Published on: September 25, 2017

8.3K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.4K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K